Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme

We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared this with HF patients with reduced ejection fraction (HFREF).

[1]  R. McKelvie,et al.  Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. , 2014, Journal of the American College of Cardiology.

[2]  C. O'connor,et al.  Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.

[3]  H. Krum,et al.  Worsening renal function during renin–angiotensin–aldosterone system inhibitor initiation and long‐term outcomes in patients with left ventricular systolic dysfunction , 2014, European journal of heart failure.

[4]  J. Cohn,et al.  Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study , 2013, European journal of heart failure.

[5]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[6]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[8]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[9]  R. Doughty,et al.  Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula , 2012, Circulation. Heart failure.

[10]  B. Pitt,et al.  Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study , 2012, Circulation.

[11]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[12]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[13]  S. Kimmel,et al.  Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction , 2011, Circulation. Heart failure.

[14]  C. Tribouilloy,et al.  Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. , 2011, International Journal of Cardiology.

[15]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[16]  D. J. Veldhuisen,et al.  Both in‐ and out‐hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH) , 2009, European journal of heart failure.

[17]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[18]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[19]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[20]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[21]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[22]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[23]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[24]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.